Chattem Q3 predictions
This article was originally published in The Tan Sheet
Executive Summary
Third quarter total revenue expected to reach $65 mil.-$67 mil., compared with previous guidance of $61 mil.-$63 mil. and year-ago sales of $49.6 mil., consumer products firm says in preliminary earnings release Sept. 12. "Strong results" were driven by Icy Hot, pHisoderm, Dexatrim and Gold Bond, "all of which experienced double-digit sales increases" over last year's Q3, Chattem says. EBITDA should reach $16 mil.-$17 mil. in Q3, compared with $11.3 mil. last year, firm predicts. FY 2003 revenue growth of 6%-8% is expected. Chattem will hold an earnings call on Sept. 27 to disclose full financial results, discuss its exit from ephedra market (1"The Tan Sheet" Sept. 9, 2002, p. 4)...
You may also be interested in...
Chattem Exiting Ephedra Market With Dexatrim Reformulations
Chattem is getting out of the ephedra business and is set to ship three reformulated Dexatrim SKUs by the end of September
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.